It has been reported that antibiotic bleomycins and their derivatives exhibit antitumor effect against several types of tumors including Ehrlich carcinoma, squamous cell carcinoma etc., but other types of tumors such as mouse ascites plasmacytoma, Friend ascites tumor, and rat ascites hepatoma are generally resistant to bleomycins. We present here the antitumor effect of aminopropylmethylpropyl-bleomycin (APMP-BLM),a new derivative of bleomycin, against a cell line of murine lymphoblastoma L5178Y resistant to aclarubicin (Y/ACR) which also expresses multidrug resistance^, but not against the parent L5178Y cell (Y/S). As presented in Table 1 , the maximumvalue of life span prolongation expressed by T/C (%) in a OCT. 1988 group of mice bearing tumors of Y/ACRcells treated with APMP-BLM at dose of 0.4 mg/kg was over 262, whereas that in a group of mice (data not shown). Again, the selective antitumor effect of the agent against Y/ACRcells was not due to selective cytotoxicity against the cell.
In an attempt to clarify the mechanism of selective antitumor effect of bleomycin against Y/ACRcells, we studied the effect of the agent Antitumor activity toward ascitic tumors of Y/S and Y/ACRcells was evaluated by determination of survival time of mice. 2 x 106 cells cultured in vitro were ip implanted into 8-week old female DBA2mice, in groups of 10, and APMP-BLM was administrated ip from day 1 to day 7 for 6 successive days once a day.
MSD:Mean survival days. Statistical analysis was performed by Student's t-test, and the marks a and b indicate jP<0.01 and JP<0.05, respectively. 
